Navigation Links
Aptivus(R) (tipranavir) Capsules Granted Full Approval by the U.S. FDA
Date:10/5/2007

additional information

on precautionary measures.

-- In clinical trials, the most frequently reported adverse events

associated with APTIVUS/r were diarrhea, nausea, fever, vomiting,

fatigue, headache and abdominal pain.

Please see full Prescribing Information (PI), including boxed WARNINGS, for APTIVUS at http://www.APTIVUS.com. The PI is in the new Physicians Labeling Rule (PLR) format required by the U.S. FDA.

Additional Information about APTIVUS

APTIVUS, a non-peptidic protease inhibitor, works by inhibiting protease, an enzyme needed to complete the HIV replication process. The approved dose of APTIVUS is 500 mg taken with 200 mg of ritonavir, twice daily.

APTIVUS is also approved in Argentina, Australia, Canada, Switzerland, Mexico, Iceland, Taiwan and the European Union.

Boehringer Ingelheim is actively conducting a clinical trial program to further evaluate APTIVUS for the treatment of HIV-1 infection. The program is comprised of ongoing and planned studies in more than 1,000 HIV-infected patients.

About Boehringer Ingelheim

Boehringer Ingelheim is committed to improving HIV therapy by providing physicians and patients with innovative antiretroviral agents.

For more information on Boehringer Ingelheim Pharmaceuticals, Inc., please visit http://us.boehringer-ingelheim.com.

(1) Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents, October 10, 2006; Treatment for Adult HIV Infection. 2006 Recommendations of the International AIDS Society - - USA Panel. JAMA. 296(7): 837. August 16, 2006.


'/>"/>
SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Allos Therapeutics PDX Granted Orphan Medicinal Product Designation by the European Commission
2. Pixantrone Granted Fast Track Designation by FDA for Relapsed Indolent NHL Patients
3. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... , July 23, 2014  Mevesi Inc. ... Fresh Media. This integration provides pharmacies with the ... current and prospective patients. Mevesi,s ... local consumer data to define target marketing campaigns. ... marketing capabilities available within the Digital Marketing, Population ...
(Date:7/23/2014)... 23, 2014  Silk Road Medical, Inc., a ... of intra- and extra-cranial cerebrovascular disease, announced today ... to the position of Chief Technology Officer.  In ... Research and Development efforts across its family of ... Prior to joining Silk Road Medical, Michael was ...
(Date:7/23/2014)... , July 23 2014 Ampio Pharmaceuticals, Inc. ... new headquarters, manufacturing and research facility: Ampio ... 80112 Direct: (720) 437-6500 Michael ... pharmaceutical drug manufacturing facility will be fully operational this ... first batches of Ampion TM necessary to accommodate ...
Breaking Medicine Technology:Mevesi Enhances Solutions with Variable Print Media Capabilities! 2Silk Road Medical Appoints Ground Breaking Innovator as Chief Technology Officer 2Silk Road Medical Appoints Ground Breaking Innovator as Chief Technology Officer 3Ampio Pharmaceuticals announces the opening of its new headquarters, manufacturing and research facility in Englewood Colorado 2
... Surgical Company (Nasdaq: STAA ), the leading ... today announced that the Visian Implantable Collamer® Lens (ICL) ... leading ophthalmologists at meetings prior to and during the ... Surgeons (ESCRS) held in Paris, France from September 4 ...
... Present at the Rodman & Renshaw Annual Global... -- SHENZHEN, China, Sept. 8 /PRNewswire-Asia/ -- ... ... --> ... var s = ,; var first_result; // Results are keyed by longUrl, so we need to grab ...
Cached Medicine Technology:STAAR Surgical Launches New Visian ICL™ Product Line Extensions at ESCRS 2STAAR Surgical Launches New Visian ICL™ Product Line Extensions at ESCRS 3STAAR Surgical Launches New Visian ICL™ Product Line Extensions at ESCRS 4STAAR Surgical Launches New Visian ICL™ Product Line Extensions at ESCRS 5STAAR Surgical Launches New Visian ICL™ Product Line Extensions at ESCRS 6Winner Medical Group Inc. to Present at the Rodman & Renshaw Annual Global Investment Conference on September 13 at 3:40 pm ET 2Winner Medical Group Inc. to Present at the Rodman & Renshaw Annual Global Investment Conference on September 13 at 3:40 pm ET 3Winner Medical Group Inc. to Present at the Rodman & Renshaw Annual Global Investment Conference on September 13 at 3:40 pm ET 4Winner Medical Group Inc. to Present at the Rodman & Renshaw Annual Global Investment Conference on September 13 at 3:40 pm ET 5Winner Medical Group Inc. to Present at the Rodman & Renshaw Annual Global Investment Conference on September 13 at 3:40 pm ET 6Winner Medical Group Inc. to Present at the Rodman & Renshaw Annual Global Investment Conference on September 13 at 3:40 pm ET 7
(Date:7/23/2014)... NY (PRWEB) July 23, 2014 The ... billion dollars by the year 2020, according to recent ... are among the top sellers in the U.S. and ... best wrinkle cream under $100 is now reviewed at ... to help a first-time or experienced shopper to compare ...
(Date:7/23/2014)... The age spots, wrinkles and puffy eyes that ... 30 are now explored in a new guide posted at ... for women over 30 are introduced in the guide as ... The use of creams as an alternative to surgery is ... according to the information in the new guide. Because there ...
(Date:7/23/2014)... Recently, iFitDress.com, a professional company of women’s ... 2014 vintage party dresses . Aside from that, it ... discount is up to 63% off. , “We are excited ... new items are all manufactured by trustworthy and experienced workers ... July 30; it is great to provide such a great ...
(Date:7/23/2014)... July 23, 2014 A new study ... power morcellator ( http://www.injurybeacon.com/power-morcellator/ ) during minimally invasive ... throughout a woman’s body, Bernstein Liebhard LLP reports. The ... Journal of the American Medical Association, looked at 36,000 ... at 500 U.S. hospitals from 2006 to 2012. Ninety-nine ...
(Date:7/23/2014)... By Steven Reinberg ... (HealthDay News) -- Many obese and overweight American children ... their weight is fine, U.S. health officials reported Wednesday. ... health outcomes, such as high blood pressure, high cholesterol ... epidemiologist at the U.S. Centers for Disease Control and ...
Breaking Medicine News(10 mins):Health News:Best Wrinkle Cream Under $100 Reviewed at Top News Website Online 2Health News:Best Eye Creams for Women Over 30 Detailed in Published Guide at News Website Online 2Health News:Cheap 2014 Vintage Party Dresses From Professional Supplier iFitDress.com 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 4Health News:Many Obese U.S. Kids Think They're Thinner Than They Are 2Health News:Many Obese U.S. Kids Think They're Thinner Than They Are 3
... as $500 would have "severe" impact on financial stability ... to climb, one often overlooked aspect of people being ... national recent survey conducted by Affinion Group, a leading ... to living paycheck-to-paycheck "often" or "always." The survey questioned ...
... Fiscal third quarter revenue from continuing operations increased $25 million, or 5%, ... , , , ... , , , , , ... , , , , , ...
... (NYSE: STE ) today announced that its Board ... dividend to $0.11 per common share. The dividend is ... close of business on May 21, 2009. About STERIS ... a healthier today and safer tomorrow through knowledgeable people and ...
... Significantly , , PRINCETON, N.J. May ... a leading worldwide provider of identity DNA testing services, today ... revenues were $14.0 million for the first quarter of 2009 ... despite the adverse impact of foreign exchange rates which reduced ...
... CARY, N.C., May 7 Cornerstone Therapeutics Inc. (Nasdaq CM: CRTX), ... products primarily for the respiratory market, today reported financial results for ... , ... or 225% , , , ...
... 10-YEAR LICENSE FOR U.S. COMMERCIAL RIGHTS TO MARKETED ... $15.5 MILLION- CORNERSTONE RECEIVES FIRST RIGHT OF OFFER ... IN THE U.S.CARY, N.C., May 7 Cornerstone ... company focused on acquiring, developing and commercializing prescription ...
Cached Medicine News:Health News:Affinion Group Survey Reveals That Underinsured Consumers Need Alternate Solutions in Light of Current Economic Climate 2Health News:Affinion Group Survey Reveals That Underinsured Consumers Need Alternate Solutions in Light of Current Economic Climate 3Health News:Perrigo Reports Record Third Quarter 2Health News:Perrigo Reports Record Third Quarter 3Health News:Perrigo Reports Record Third Quarter 4Health News:Perrigo Reports Record Third Quarter 5Health News:Perrigo Reports Record Third Quarter 6Health News:Perrigo Reports Record Third Quarter 7Health News:Perrigo Reports Record Third Quarter 8Health News:Perrigo Reports Record Third Quarter 9Health News:Perrigo Reports Record Third Quarter 10Health News:Perrigo Reports Record Third Quarter 11Health News:Perrigo Reports Record Third Quarter 12Health News:Perrigo Reports Record Third Quarter 13Health News:Perrigo Reports Record Third Quarter 14Health News:Perrigo Reports Record Third Quarter 15Health News:Perrigo Reports Record Third Quarter 16Health News:Perrigo Reports Record Third Quarter 17Health News:Perrigo Reports Record Third Quarter 18Health News:Perrigo Reports Record Third Quarter 19Health News:Perrigo Reports Record Third Quarter 20Health News:Perrigo Reports Record Third Quarter 21Health News:Perrigo Reports Record Third Quarter 22Health News:STERIS Corporation Announces Quarterly Dividend Increase of 38% 2Health News:STERIS Corporation Announces Quarterly Dividend Increase of 38% 3Health News:Orchid Cellmark Reports Improved First Quarter 2009 Financial Results 2Health News:Orchid Cellmark Reports Improved First Quarter 2009 Financial Results 3Health News:Orchid Cellmark Reports Improved First Quarter 2009 Financial Results 4Health News:Orchid Cellmark Reports Improved First Quarter 2009 Financial Results 5Health News:Orchid Cellmark Reports Improved First Quarter 2009 Financial Results 6Health News:Orchid Cellmark Reports Improved First Quarter 2009 Financial Results 7Health News:Orchid Cellmark Reports Improved First Quarter 2009 Financial Results 8Health News:Orchid Cellmark Reports Improved First Quarter 2009 Financial Results 9Health News:Cornerstone Therapeutics Reports First Quarter 2009 Financial Results 2Health News:Cornerstone Therapeutics Reports First Quarter 2009 Financial Results 3
... Fit™ is the innovative, new padding system ... cushions bony prominences and contours to the ... other padding around. Plus, Gel Fit's proprietary ... creating a vacuum seal when the brace ...
... Flex™ might just be the world's ... for functional support, post-op/rehab support, or both, ... Flex's new Accutrac™ ROM hinges control flexion ... provides long-term durability while being heat-moldable to ...
... state-of-the-art laser scanning technology for an anatomically-contoured, ... lean, athletic legs. Offering the same ... Flex Sport's "second skin" fit conforms to ... no other off-the-shelf knee brace., ,Indications: ...
... CartiCare enables unloading of the medial or ... with unicompartmental osteoarthritis. Plus, we equipped this ... hinge, making it further suitable for post-op ... and/or adjustable flexion/extension control. , ,Indications: ...
Medicine Products: